12 April 2022 - Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death and hospitalisation for chronic heart failure.
Health Canada has granted marketing authorisation for Jardiance (empagliflozin) 10 mg for the treatment of chronic heart failure in adults as an adjunct to standard of care therapy, Boehringer Ingelheim and Eli Lilly have announced.